Gain Therapeutics (GANX) Total Liabilities (2020 - 2026)
Gain Therapeutics (GANX) posted quarterly Total Liabilities of $4.7 million for Q1 2026, down 19.04% year-over-year from $5.8 million in Q1 2025, and up 11.22% quarter-over-quarter from $4.3 million in Q4 2025.
Gain Therapeutics (GANX) Total Liabilities (2020 - 2026) Analysis & Trends
Gain Therapeutics' Total Liabilities history runs 7 years deep, the most recent figure standing at $4.7 million for Q1 2026.
- In Q1 2026, Total Liabilities fell 19.04% year-over-year to $4.7 million; the TTM figure through Mar 2026 stood at $4.7 million (down 19.04% YoY), while the FY2025 annual figure was $4.3 million, down 11.08% from the prior year.
- Total Liabilities for Q1 2026 stood at $4.7 million, up from $4.3 million in the prior quarter.
- The five-year high for Total Liabilities was $7.4 million in Q2 2024, with the low at $4.3 million in Q4 2025.
- The 5-year median for Total Liabilities is $5.8 million (2022), against an average of $5.7 million.
- The sharpest annual moves came in 2022 and 2023: Total Liabilities slumped 89.25% in 2022, then soared 47.09% in 2023.
- Gain Therapeutics' Total Liabilities stood at $5.2 million in 2022, then gained by 15.54% to $6.0 million in 2023, then retreated by 20.67% to $4.8 million in 2024, then retreated by 11.08% to $4.3 million in 2025, then advanced by 11.22% to $4.7 million in 2026.
- Business Quant data shows GANX's Total Liabilities at $4.7 million in Q1 2026, $4.3 million in Q4 2025, and $5.1 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 7.18 Bn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 10.02 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | 1.62 Bn |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | 4.20 Bn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 4.00 Bn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 4.20 Bn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | 1.35 Bn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 10.03 Bn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | 3.22 Bn |
| 10 | Gain Therapeutics | 85.12 Mn | 85.12 Mn | - | 4.13 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 4.13 Mn |
| Mar 31, 2026 | 4.73 Mn |
| Dec 31, 2025 | 4.25 Mn |
| Sep 30, 2025 | 5.06 Mn |
| Jun 30, 2025 | 6.14 Mn |
| Mar 31, 2025 | 5.84 Mn |
| Dec 31, 2024 | 4.78 Mn |
| Sep 30, 2024 | 5.46 Mn |
| Jun 30, 2024 | 7.41 Mn |
| Mar 31, 2024 | 5.94 Mn |
| Dec 31, 2023 | 6.03 Mn |
| Sep 30, 2023 | 6.77 Mn |
| Jun 30, 2023 | 7.17 Mn |
| Mar 31, 2023 | 6.18 Mn |
| Dec 31, 2022 | 5.22 Mn |
| Sep 30, 2022 | 5.66 Mn |
| Jun 30, 2022 | 4.87 Mn |
| Mar 31, 2022 | 5.77 Mn |
| Dec 31, 2021 | 4.17 Mn |
| Sep 30, 2021 | 42.56 Mn |